

## **MiMedx to Present at the American Academy of Orthopaedic Surgeons Annual Meeting**

January 25, 2012 4:26 PM ET

**PRESS RELEASE Contact: Michael Senken  
Phone: (678) 384-6720**

### **MiMedx to Present at American Academy of Orthopaedic Surgeons Annual Meeting**

**KENNESAW, Georgia, January 25, 2012** (PR Newswire) – MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that they will be attending the American Academy of Orthopaedic Surgeons (AAOS) annual meeting, February 8 through February 10, 2012. The AAOS 2012 annual meeting will be held at the Moscone Center in San Francisco, California.

MiMedx will be presenting the Company's biomaterial platform technologies developed for use in soft tissue trauma, nerve repair, spinal applications and sports medicine. During the conference, MiMedx will be presenting HydroFix<sup>®</sup>, one its device technologies, and AmnioFix<sup>®</sup>, one of is tissue technologies, and highlighting the Company's offerings, AmnioFix<sup>®</sup> Injectable and AmnioFix<sup>®</sup> Wrap.

Throughout the conference, MiMedx plans to sponsor various meetings with physicians and scientists to discuss and demonstrate the benefits and potential of these offerings. MiMedx Group will be located in Booth 2309 at the Moscone Center.

#### **About the Company**

MiMedx<sup>®</sup> is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the device technologies HydroFix<sup>®</sup> and CollaFix<sup>™</sup>, and our tissue technologies, AmnioFix<sup>®</sup> and EpiFix<sup>®</sup>. Our tissue technologies, processed from the human amniotic membrane, utilize our proprietary Purion<sup>™</sup> process that was developed by our wholly-owned subsidiary, Surgical Biologics, to produce a safe, effective and minimally manipulated implant. Surgical Biologics is the leading supplier of amniotic tissue, having supplied over 60,000 implants to date to distributors and OEMs for application in the Ophthalmic, Orthopedics, Spine, Wound Care and Dental sectors of healthcare.